Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Free Cash Flow (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Free Cash Flow for 7 consecutive years, with -$18.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 64.87% to -$18.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$128.7 million, a 19.23% increase, with the full-year FY2025 number at -$128.7 million, up 19.23% from a year prior.
  • Free Cash Flow was -$18.0 million for Q4 2025 at Pliant Therapeutics, up from -$21.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$13.9 million in Q1 2021 to a low of -$51.4 million in Q4 2024.
  • A 5-year average of -$28.7 million and a median of -$24.6 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 357.05% in 2021, then surged 64.87% in 2025.
  • Pliant Therapeutics' Free Cash Flow stood at -$18.6 million in 2021, then tumbled by 59.72% to -$29.6 million in 2022, then rose by 18.23% to -$24.2 million in 2023, then plummeted by 111.94% to -$51.4 million in 2024, then soared by 64.87% to -$18.0 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Free Cash Flow are -$18.0 million (Q4 2025), -$21.1 million (Q3 2025), and -$40.6 million (Q2 2025).